PDE10

PDE10 Related Products (24):

By Type:	Pan (14) Selective (4)

Cat. No.	Product Name	Effect	Purity

HY-18252

Avanafil	Inhibitor	98.66%
Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis.

HY-50098

Mardepodect	Inhibitor	99.04%
Mardepodect (PF-2545920) is a potent, orally active and selective PDE10A inhibitor with an IC₅₀ of 0.37 nM, with >1000-fold selectivity over other PDEs. Mardepodect can cross the blood-brain barrier.

HY-111371

PF-05180999	Inhibitor	99.97%
PF-05180999 (PF-999) is a phosphodiesterase 2A (PDE2A) inhibitor, with an IC₅₀ of 1.6 nM.

HY-153093

MK-8189	Inhibitor	99.88%
MK-8189 is a potent, orally active and selective PDE10A inhibitor with a K_i value of 29 pM. MK-8189 can be used in research of schizophrenia.

HY-100530C

Sp-cAMPS sodium salt	Inhibitor	99.45%
Sp-cAMPS sodium salt, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS sodium salt is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a K_i of 47.6 µM. Sp-cAMPS sodium salt binds the PDE10 GAF domain with an EC₅₀ of 40 μM.

HY-161663

Phosphodiesterase-IN-2	Inhibitor
Phosphodiesterase-IN-2 (Compound C7) is a selective, orally active inhibitor for phosphodiesterase 10A (PDE10A), with an IC₅₀ of 11.9 nM. Phosphodiesterase-IN-2 improves the stability of liver microsomes, and lowers BBB permeability. Phosphodiesterase-IN-2 exhibits good pharmacokinetic characters, and attenuates isoprenaline (HY-108353)-induced cardiac hypertrophic in mouse models.

HY-50098A

Mardepodect hydrochloride	Inhibitor	99.94%
Mardepodect hydrochloride (PF-2545920 hydrochloride) is a potent, orally active and selective PDE10A inhibitor with an IC₅₀ of 0.37 nM, with >1000-fold selectivity over other PDEs. Mardepodect hydrochloride can cross the blood-brain barrier.

HY-18078

PQ-10	Inhibitor	99.77%
PQ-10 is a potent inhibitor of Phosphodiesterase 10A (PDE10A) with IC₅₀ andED₅₀ of 4.6 nM and 13 mg/kg, respectively. PQ-10 induces patterns of brain glucose metabolism which can be a potential translational biomarker. PQ-10 has the potential for researching psychiatric disorders like schizophrenia.

HY-100530B

Sp-cAMPS	Inhibitor
Sp-cAMPS, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a K_i of 47.6 µM. Sp-cAMPS binds the PDE10 GAF domain with an EC₅₀ of 40 μM.

HY-131973

PDE10A-IN-2 hydrochloride	Inhibitor	98.43%
PDE10A-IN-2 hydrochloride is a potent, highly selective and orally active phosphodiesterase 10A (PDE10A) inhibitor with an IC₅₀ of 2.8 nM. PDE10A-IN-2 hydrochloride shows selectivity of >3500-fold against other PDE subtypes. PDE10A-IN-2 hydrochloride can be used for pulmonary arterial hypertension (PAH) research.

HY-135848

N-Methylbenzamide	Inhibitor	99.93%
N-Methylbenzamide is a potent phosphodiesterase 10A (PDE10A) inhibitor. N-Methylbenzamide has anti-cancer activity.

HY-12813

PDE10-IN-1	Inhibitor	99.44%
PDE10-IN-1 is a potent PDE10-IN-1 inhibitor extracted from Patent WO 2013192273 A1, for treating CNS and metabolic disorders.

HY-U00427

PDE2/PDE10-IN-1	Inhibitor	99.88%
PDE2/PDE10-IN-1 is a phosphodiesterase 2 (PDE2) and PDE10 inhibitor with IC₅₀s of 29 and 480 nM, respectively.

HY-18252A

Avanafil dibenzenesulfonate	Inhibitor
Avanafil (TA-1790) dibenzenesulfonate is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil dibenzenesulfonate activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil dibenzenesulfonate inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil dibenzenesulfonate can be used for the research of erectile dysfunction and osteoporosis.

HY-112704

PDE5-IN-2	Inhibitor
PDE5-IN-2 is a potent, highly selective, and orally active PDE5 inhibitor, with an IC₅₀ of 0.31 nM, less potently inhibits PDE2A, PDE10A, PDE4D2, and PDE6C, with IC₅₀s of 106, 46, 43, 1.2 nM, respectively. Anti-pulmonary arterial hypertension activity.

HY-128349

MT-3014	Inhibitor
MT-3014 is a potent, highly selective and brain-penetrated phosphodiesterase 10A (PDE 10A) inhibitor, with IC₅₀s of 0.062 nM and 0.09 nM for human PDE 10A and bovine PDE 10A, respectively.

HY-110005

Sp-cAMPS triethylamine	Inhibitor
Sp-cAMPS triethylamine, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS triethylamine is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a K_i of 47.6 µM. Sp-cAMPS triethylamine binds the PDE10 GAF domain with an EC₅₀ of 40 μM.

HY-124775

(S)-C33	Inhibitor	99.46%
(S)-C33 is a potent and selective PDE9 (phosphodiesterase-9) inhibitor, with an IC₅₀ of 11 nM. (S)-C33 can be used for central nervous system diseases and diabetes research.

HY-152838

Gemlapodect	Inhibitor
Gemlapodect (RO554965) is an inhibitor of phosphodiesterase 10A (PDE10A). Gemlapodect can be used for researching schizophrenia.

HY-151174

PDE4-IN-12	Inhibitor
PDE4-IN-12 is a potent pan-PDE4 inhibitor, with IC₅₀s of 3.5 and 15 nM for PDE4 and PDE7, respectively (SI=2.71 and 4.27, respectively). PDE4-IN-12 shows well tolerated, can be used in study of inflammatory bowel diseases (IBDs).

Name
Email *

	Sorry, but the email address you supplied was invalid.